We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Genomic Analysis Uncovers Differences in Liver Cancer Subtypes

By LabMedica International staff writers
Posted on 05 Jun 2019
Intrahepatic cholangiocarcinoma (ICC) is the second most common malignancy arising from the liver. More...
ICC makes up about 10% of all cholangiocarcinomas. It arises from the peripheral bile ducts within the liver parenchyma, proximal to the secondary biliary radicals.

Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare type of primary liver cancer comprising histopathological features of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Because of its rarity and controversial diagnostic criteria, it continues to be poorly understood with a lack of well-delineated treatment options for recurrent or metastatic disease.

A large team of scientists working with those at Peking University (Beijing, China) sequenced the genomes and transcriptomes of 133 cHCC-ICC cases, including ones belonging to the separate, combined, and mixed cHCC-ICC subtypes. In their pan-Asia, multi-center study they analyzed the cHCC-ICC samples using a combination of whole-exome, whole-genome, RNA, and single-nucleus sequencing. Based on established criteria, they were able to categorize 121 of these cHCC-ICC cases as separate, combined, or mixed cHCC-ICC subtypes.

Among all these samples, the most significantly mutated genes were TP53, AXIN1, and RB1, while signaling pathways involved in histone modification and DNA methylation were commonly altered in cHCC-ICC. In addition, they noted noncoding and structural variation, including variations affecting the TERT promoter and fusion genes as well as focally amplified and deleted regions. They also compared the mutational landscape of these cHCC-ICC samples with those found in HCC and ICC, finding that TP53 was mutated in nearly half of cHCC-ICC cases, much higher than in either HCC or ICC tumors, while cHCC-ICC cases had lower rates of CTNNB1 mutations than HCCs and lower rates of KRAS mutations than ICC.

The scientists suggested that the previous controversy over whether or not cHCC-ICC is a distinct type of liver cancer could be due to previous work only sampling one of these cHCC-ICC subtypes that resembled ICC or HCC to a certain extent. Both mixed and combined cHCC-ICCs are associated with a stem-like feature and exhibit poor prognosis, the team noted. Both types have high expression of nestin, a marker for the bipotent progenitor oval cell, which may give cancer cells high cellular plasticity. When they compared nestin levels in the various cHCC-ICC subtypes to HCC and ICC, they found that more than 80% of the cHCC-ICC samples had higher nestin levels than the HCC or ICC samples. This suggests that nestin may serve as a biomarker for diagnosing cHCC-ICC. The study was published on May 23, 2019, in the journal Cancer Cell.

Related Links:
Peking University


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.